Which medicine is best for treating hepatitis C: Jisandai or Bingtonsha?

Epclusa and Epclusa are actually the same drug, and the two names refer to the same drug used to treat hepatitis C (HCV). They differ only in the naming of different regions. In some areas, Jisandai is used as the trade name of the drug, while in other areas, such as the Chinese market, it is called Bingtonsa. Therefore, these two names do not represent different drugs, but different names for the same drug.

Epclusa is a direct antiviral drug against hepatitis C virus (HCV) developed by Gilead Sciences. It contains two active ingredients: Sofosbuvir and Velpatasvir. The combined use of these two ingredients can effectively inhibit the replication of hepatitis C virus and treat different genotypes of hepatitis C, especially for types 1 to 6 hepatitis C.

As a broad-spectrum antiviral drug, Gisanda is suitable for adult patients without cirrhosis or mild cirrhosis, as well as patients with partial liver damage. The advantage of this drug is its wide therapeutic range, short treatment course (usually 12 weeks), and relatively few side effects. As the global treatment standard for hepatitis C gradually shifts to direct-acting antiviral drugs (DAAs), the application of GIS has become more and more widely used, becoming one of the first-choice drugs for the treatment of hepatitis C.

However, regarding the question of "which drug is best for treating hepatitis C?", since Jisandai and Bingtongsha are the same drugs, there is no need to compare their therapeutic effects. Whether it is the original drug Jisandai or Bingtongsha, their therapeutic effects are the same. The key lies in the patient's specific circumstances, including hepatitis C genotype, extent of liver damage, and other complications. The doctor will recommend the most appropriate treatment plan based on these factors.

Reference: https://www.epclusa.com/